Advertising Survey

We would like your input on how advertising is currently used in the site.

Please take this short survey to help us out.

Hide this message

Henoch-Schönlein Purpura

This PatientPlus article is written for healthcare professionals so the language may be more technical than the condition leaflets. You may find the abbreviations list helpful.

Henoch-Schönlein purpura (HSP) is an IgA-mediated, autoimmune, hypersensitivity vasculitis of childhood. The main clinical features are skin purpura, arthritis, abdominal pain, gastrointestinal bleeding, orchitis and nephritis. The aetiology remains unknown.

Epidemiology

  • In the United Kingdom, the estimated annual incidence is 20 cases per 100,000 population.1
  • The peak prevalence is in children aged 3-10 years. It is rare in infants and young children.
  • The male-to-female ratio is 1.5-2:1. Whites are more affected than blacks.

Risk factors

Associated conditions preceding HSP include:

Presentation

  • The disease occurs mostly in the winter months. About 50% of patients have a preceding upper respiratory tract infection (URTI).3
  • Generally, patients appear to be mildly ill, with low-grade fever.
  • Symmetrical erythematous macular rash, especially on the back of the legs, buttocks and ulnar side of the arms.
  • Within 24 hours, the macules evolve into purpuric lesions, which may coalesce and resemble bruises.
  • Abdominal pain and bloody diarrhoea may precede the typical purpuric rash. Intussusception should then be considered (occurs in 2-3% of patients). HSP may also cause nausea and vomiting.
  • Joint pain, especially knees and ankles. Joints may also be swollen and tender but permanent deformity does not occur.
  • Renal involvement:
    • Affects 50% of older children and 25% of children under 2 years of age.
    • Less than 1% of patients progress to end stage renal disease.
    • Usually occurs within 3 months of disease onset.
    • There is usually no relationship between the severity of nephritis and the extent of the other manifestations of HSP.
    • Microscopic haematuria with mild-to-moderate proteinuria may occur.
    • Nephrotic syndrome may also occur.
    • Oliguria and hypertension are rare.
  • Scrotal involvement may mimic testicular torsion.
  • Neurological: headaches may occur.

Differential diagnosis

Investigations

Diagnosis of HSP is clinical and not based on laboratory investigations.3 The following abnormalities may be present:

  • Urinalysis: haematuria and/or proteinuria are present in 10-20% of patients.3
  • FBC: may be raised white cell count with eosinophilia; normal or increased platelets
  • Raised ESR
  • Serum creatinine may be elevated in renal involvement
  • Serum IgA levels are often increased
  • Autoantibody screen: connective tissue diseases
  • Abdominal ultrasound: if gastrointestinal symptoms - for diagnosis of intestinal obstruction
  • Barium enema: may be used to confirm and treat intussusception
  • Testicular ultrasound: assessment of possible torsion
  • Renal biopsy: if persistent nephrotic syndrome

Management

  • HSP is usually self-limiting and no form of therapy has been shown appreciably to shorten the duration of disease or prevent complications. Therefore treatment for most patients remains primarily supportive.
  • Non-steroidal anti-inflammatory drugs may help joint pain but should be used with caution in patients with renal insufficiency.
  • May require admission to hospital for monitoring of abdominal and renal complications.
  • Nephropathy: treated supportively. A variety of drugs (steroids, azathioprine, cyclophosphamide) and plasmapheresis have been used to prevent the progression of the renal disease but the results of trials have been inconsistent.5
  • Corticosteroids can ameliorate associated arthralgias and the symptoms associated with gastrointestinal dysfunction. There was no evidence of benefit of prednisone in preventing serious long-term kidney disease in HSP.6
  • No controlled clinical trials have been performed with immunosuppressive drugs, although azathioprine or cyclophosphamide may be beneficial.5
  • Plasma exchange is used in the management of some adults with vasculitis and idiopathic rapidly progressive nephritis.5

Complications

  • Renal involvement occurs in 50% of older children but is only serious in approximately 10% of patients. Less than 1% of patients with HSP progress to end-stage renal failure.3 The renal prognosis is worse in older children and adults.
  • Monitoring for renal involvement:7
    • A review found that no long-term renal impairment occurred after normal urinalysis.
    • If urinalysis is normal at presentation, the review recommends that testing should be continued for six months.
    • There is no need to follow up after the first six months those whose urinalysis remains normal.
  • Other rare complications include myocardial infarction, pulmonary haemorrhage, pleural effusion, intussusception (in 2-3% of patients), gastrointestinal bleeding, bowel infarction, seizures and mononeuropathies.
  • Recurrence of symptoms may occur. Recurrence of renal impairment may also occur but is rare.

Prognosis

  • HSP is an acute self-limited illness and usually resolves without treatment, but may rarely lead to complications. Initial attacks of HSP can last several months. One third of patients have one or more recurrences.
  • Children younger than 3 years have a shorter, milder course and fewer recurrences.
  • The long-term prognosis of HSP is directly dependent on the severity of renal involvement.8


Document references

  1. Gardner-Medwin JM, Dolezalova P, Cummins C, et al; Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002 Oct 19;360(9341):1197-202. [abstract]
  2. Lane SE, Watts R, Scott DG; Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005 Aug;7(4):270-5. [abstract]
  3. Bossart P; Henoch-Schonlein Purpura; eMedicine, June 2009.
  4. Shetty AK, Desselle BC, Ey JL, et al; Infantile Henoch-Schonlein purpura. Arch Fam Med. 2000 Jun;9(6):553-6. [abstract]
  5. Tizard EJ; Henoch-Schonlein purpura. Arch Dis Child. 1999 Apr;80(4):380-3.
  6. Chartapisak W, Opastirakul S, Hodson EM, et al; Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005128. [abstract]
  7. Narchi H; Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005 Sep;90(9):916-20. Epub 2005 May 4. [abstract]
  8. Saulsbury FT; Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999 Nov;78(6):395-409. [abstract]

Internet and further reading

Acknowledgements

EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2009.
Document ID: 2251
Document Version: 21
Document Reference: bgp1227
Last Updated: 4 Sep 2009
Provide feedback